Losartan: A review of its role in hypertension and other cardiovascular diseases

Canadian Journal of Clinical Pharmacology

Volumn 3, Issue 3, 1996, Pages 126-135

  Paradiso Hardy, Fran L ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Angiotensin II receptor; Cardiovascular disease; Losartan; Renin angiotensin aldosterone system; Review

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; ATENOLOL; BRADYKININ; CIMETIDINE; CISAPRIDE; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; SULFAPHENAZOLE;

ADULT; AGED; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VERTIGO;

EID: 0029909502     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994;12:1177-81.
2. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens 1994;12(Suppl 9):S17-22.
3. Weber K, Janicki J. Angiotensin and the remodelling of the myocardium. Br J Clin Pharm 1989;28(Suppl 2):S141-50.
4. Katoh Y, Komuro I, Shibasaki I, Yamaguchi H, Yazaki Y. Angiotensin II induces hypertrophy and oncogene expression in cultured rat heart myocytes. Circulation 1989;80(Suppl I): II450.
5. Fogari R, Zoppi A, Tettamanti F, Malamani G, Tinelli C, Salvetti A. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992;19:670-3.
6. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovas Pharmacol 1990;15:276-82.
7. Cody R. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994;47:586-98.
8. Foote E, Halstenson C. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors. Ann Pharmacother 1993;27:1495-503.
9. Abdelrahman A, Burrell L, Johnston C. Blockade of the renin-angiotensin system at different sites: effect of renin, angiotensin and aldosterone. J Hypertens 1993;11(Suppl 3):S23-6.
10. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995;25:924-7.
11. Case D, Wallace J, Keirn H, Sealey J, Laragh J. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976;60:825-36.
12. Cozaar Product Monograph. Kirkland: Merck Frosst, 1995.
13. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-7.
14. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
15. Stearns R, Chakravarty P, Chen R, Chiu S. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos Biol Fate Chem 1995;23:207-15.
16. Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994;27:216-48.
17. Shaw W, Keane W, Sica D, et al. Safety and antihypertensive effects of losartan (MK954:DUP753), a new angiotensin II receptor antagonist, in patients with hypertension and renal disease. Clin Pharmacol Ther 1993;Suppl:140.
18. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
19. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
20. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation 1991;83:1333-42.
21. Goldberg M, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13.
22. Doig J, MacFadyen R, Sweet C, Lees K, Reid J. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993;21:732-8.
23. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992;5:19A-20A.
24. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:280-32.
25. Gansevoort R, De Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl 2):S37-42.
26. Kieldsen S, Moan A, Sweet C, et al. Treatment with the angiotensin II (AII) receptor antagonist losartan in 180 patients with severe hypertension. Am J Hypertens 1994;7:33A-51A.
27. Weber M, Byyny R, Pratt H, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-11.
28. Soffer B, Wright J, Pratt J, Wiens B, Goldberg A, Sweet C. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7.
29. Gradman A, Arcuri K, Goldberg A, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.
30. Goldberg M, Bradstreet T, McWilliams E, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
31. Dahlof B, Keller S, Makris L, Goldberg A, Sweet C, Lim N. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995;8:1-6.
32. Chan J, Critchley J, Lappe J, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995;9:1-7.
33. Goldberg A, Dunlay M, Sweet C. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-5.
34. Bies R, Robert R. Molecular biology of the cardiovascular system. In: Stein J, ed. Internal Medicine, 4th edn. St Louis: Mosby Year Book, 1994:15-31.
35. Hamet P, Richard L, Dam T, et al. Apoptosis in target organs of hypertension. Hypertension 1995;26:642-8.
36. Linz W, Scholkens B. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
37. Mizuno K, Tani M, Hashimoto S, et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992;51:367-74.
38. Smits J, van Crimpen C, Schoemaker R, Cleutjens J, Daeman M. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1993;20:772-8.
39. Raya T, Fonken S, Lee R, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition to the rat model of heart failure. Am J Hypertens 1991;4(Suppl):S334-40.
40. Konstam M, Rousseau M, Kronenberg M, et al. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
41. Yusuf S, Pepine C, Bourassa M, Garces C, Pitt B. Effect on enalapril on the development of myocardial infarction and unstable angina. J Am Coll Cardiol 1992;19(Suppl):210A. (Abst)
42. The SOLVD Investigators. The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-35.
44. Enalapril Congestive Heart Failure Investigators. Long-term effect of enalapril in congestive heart failure: a multicenter placebo-controlled trial. Heart Failure 1987;3:102-7.
45. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
46. Gottlieb S, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-9.
47. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-7.
48. Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994;12(Suppl 2):S31-5.
49. Sweet C, Rucinska E. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994;15(Suppl D):139-44.
50. Anderson S, Brenner B. Role of intraglomerular hypertension in the initiation and progression of renal disease. In: Kaplan NBB, Laragh JE, eds. The Kidney in Hypertension. Perspectives in Hypertension, vol 1. New York: Raven Press, 1987:67-76.
51. Melchior W, Bindlish V, Jaber L. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother 1993;27:344-50.
52. Mason N. Angiotensin-converting enzyme inhibitors and renal function. Ann Pharmacother 1990;24:496-505.
53. Gansevoort R, De Zeeuw D, De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
54. Acker C, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995;333:1572. (Lett)
55. Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
56. Faison E, Snavely D, Thiyagarajan B, Nelson E. The incidence of cough with the angiotensin II receptor antagonist (AngII RA), losartan, is significantly less than with angiotensin converting enzyme (ACE) inhibitors (ACEI) and is similar to that of placebo. Am J Hypertens 1994;7:34A.
57. Nelson E, Merrill D, Sweet C, et al. Efficacy and safety of oral MK-954 (Dup753) an angiotensin II antagonist in essential hypertension. J Hypertens 1991(Suppl 6):S408-69.
58. Weber M. Clinical experience with the angiotensin II receptor antagonist Losartan. A preliminary report. Am J Hypertens 1992;5:S247-51.
59. Burner M, Waeber B, Brunner H. The advantages of angiotensin II antagonism. J Hypertens 1994;12:S7-15.
60. Xie M, Liu F, Wong P, et al. Proximal nephron and renal effects of DuP753, a nonpeptide AngII receptor antagonist. Kidney Int 1990;38:473-9.
61. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5.
62. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an AngII antagonist in healthy subjects. Hypertension 1993;22:339-47.
63. Miyais S, Kauffman S, Katz A. Angiotensin II binding sites in individual segments of the rat nephron. J Clin Invest 1986;77:315-8.
64. Report of a Canadian Hypertension Society Consensus Conference: 3. Pharmacologic Treatment of Essential Hypertension. Can Med Assoc J 1993;149:575-84.
65. MacFadyen R, Reid J. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994;12:1333-8.